Get started

Jnj_setup

Johnson & Johnson | JNJ | Long at $146.00Johnson & Johnson NYSE:JNJ is strong (but highly controversial) company with anticipated earnings growth on the horizon. With a P/E of 23x, steady dividend growth record, low debt, and expected increased cashflow, the future is optimistic for NYSE:JNJ if they can stay out of the shady spotlight... While the historical simple moving average I've selected suggests the stock is entering a downtrend on the daily chart, I'm going to go against this given the current price/position it is in. If the price can hold in $140's and then move up, there could be an early cup formation here. However, if the price drops below $140, that idea is out, and the near-term downtrend may be on. But the company, overall, is a personal buy-and-hold for the long-term ups and downs (unless new news points the company in a different direction). Thus, at $146.00, NYSE:JNJ is in a personal buy-zone. Target #1 = $157.00 Target #2 = $165.00 Target #3 = $170.00+
NYSE:JNJLong
by WorthlessViews
JNJ - 3 Day Timeframe - Area to load up??Hi guys welcome. The ideas expressed on this chart are my own opinions. This is not financial advice and i am not a financial advisor. Im a student of the charts and do this to improve my skills. Anyway, i posted a JNJ chart last week on the Weekly timeframe. Mentioning how it could be a good time to buy some as we are touching up against the 200 week moving average and hitting some major support. This chart is looking at JNJ on the 3D timeframe. Zooming in just a little bit. I will follow this with a daily chart next to zoom in even more. Please note: The current candle on 3D will close on the 24th. So this current move is not yet finished and i believe we could touch the support line again or even wick down below. But as coinciding with the 200 Week moving average on the Weekly timeframe, this if history is any indication generally a good time to get some exposure. (please check the weekly JNJ chart below). So like the previously posted chart on weekly, ive circled in green some instances in the past where it was essentially a good swing trade entry point. It can also be an area to load up for investing since long term trend is up and it being a dividend stock and all....... (this is not financial advise!) For this chart, the story is told in the indicators ive provided. From top to bottom: 1. STOCH RSI - momentum indicator 2. MACD - momentum indicator 3. RSI - supply/demand indicator The RSI to me sticks out the most, as we are below the 20 level and the most "Oversold" we have ever been since March 2020, (coinciding with my weekly chart of the price action going below the 200 wma briefly). To add confluence and support to this idea, i added the other 2 indicators to show oversold momentum areas. And all 3 indicators mimic'd similar patterns to those past instances. The conditions that need to be met simultaneously to buy: 1.on 3D timeframe: 1. RSI below 20 level 2. MACD below 0 level, red bars 3. STOCH RSI below 20 level 4. Price action below 200 dma on 3D timeframe 2. on weekly timeframe: Price action (candles) touching or below the 200 week moving average I like this current area as not only are we touching the 200 weekly moving average, we are hitting some major support. (Check out my weekly chart for more info on this) Make sure to check it out yourself on your charts! Let me know what yall think. Please comment, like, & follow if you liked this analysis. Remember to trade responsibly, to set up your own strategies and to protect yourself with stop loss. Disclaimer: This is not financial advise, i am not a financial advisor. This info is only my own opinion on the matter of TA.
NYSE:JNJLong
by SafofAllTrades
Johnson & Johnson|Fundamental Analysis|Price action| MUST READ!In a nutshell, Johnson & Johnson's third-quarter results were generally good. The company reported a 10.7% year-over-year increase in revenue to $23.3 billion. Adjusted earnings per share rose 18.2% to $2.60, well above the consensus estimate of $2.35. Given the large earnings outperformance, you'd probably think the health care company's stock should have rallied Tuesday after the quarterly report was released. And you'd be right. J&J stock opened up about 1% and gained even more momentum during the day. Perhaps the rise would have been greater had it not been for the company's third-quarter earnings, which came in below analysts' average forecast of $23.7 billion. But there was more to this story for the health care giant than just the underlying numbers. Here are three things you might have missed about Johnson & Johnson's third-quarter results. First and foremost, three products accounted for 63% of the growth. Many investors love Johnson & Johnson largely because of its diversification. The company has three multi-billion dollar business segments targeting different areas of healthcare. Hundreds of products are sold in these segments. In 2020, J&J claimed 28 products or platforms with annual sales of more than $1 billion. Although Johnson & Johnson's business is broadly diversified, the drivers of its growth in the third quarter were not. Just three products accounted for about 63% of the company's total revenue growth. These products accounted for nearly 90% of J&J's pharmaceutical sales growth. Not surprisingly, the COVID-19 vaccine tops the list. It brought in $502 million in the third quarter, up from no revenue the previous year. The multiple myeloma drug Darzalex took a respectable second place. Sales of the drug totaled $1.58 billion in the third quarter, up 43.7% from nearly $1.1 billion in the same quarter in 2020. J&J's Stelara drug was the third-largest growth driver in the third quarter. Sales of the plaque psoriasis and psoriatic arthritis drug totaled $2.38 billion in the quarter. That's a 22.2% increase over sales of $1.95 billion in the previous quarter. Second, it's important to keep in mind that the COVID-19 pandemic continues to have a major impact beyond just the vaccine. Johnson & Johnson's COVID-19 vaccine certainly contributed significantly to the good third-quarter results. And it could make an even bigger furor in the future. J&J is likely to benefit significantly from booster sales (if, as expected, it gets approved for boosters). However, COVID-19 also continues to have a significant impact on J&J's fortunes beyond the vaccine. Johnson & Johnson's consumer health business, for example, has been helped by increased sales of the drug Tylenol. The company noted that some of the increase in sales of the over-the-counter drug was due to its use to relieve vaccine-induced symptoms. J&J also reported that sales of ORSL HCP electrolyte drinks increased due to relief of COVID-19 symptoms. It wasn't all good news, however. Sales bans in parts of the Asia-Pacific region had a negative impact on sales of baby care products. The company said growth in sales of its Imbruvica cancer drug was partially held back by COVID-19-related dynamics. In addition, sales of J&J's orthopedic medical products in the spine, sports, and other category fell mainly because of the impact of COVID-19 on the market. Finally, the company is now on the cusp of an international tipping point. Although based in the U.S., Johnson & Johnson has been a major competitor in global markets for most of its history. And now the health care giant is nearing a crucial international stage. In the third quarter, J&J's U.S. sales rose 7.9 percent year over year to just under $12 billion. Its international sales jumped 13.8% to $11.4 billion. International markets now account for 48.7% of total revenue. At the current rate of growth, by next year more than half of Johnson & Johnson's revenue will come from outside the United States. Investors should see this as a decidedly positive trend. Greater geographic diversification of revenues could make Johnson & Johnson even more stable than it is now.
NYSE:JNJShort
by FOREXN1
6
JNJ: Bearish Breakdown Analysis 4H (Apr. 26)X FORCE GLOBAL ANALYSIS: Johnson & Johnson has shown great momentum in its small rally over the past few weeks. However, technicals demonstrate signs of prices having temporarily topped out. Technical Analysis - The first thing we spot is a textbook bearish divergence. - Prices form higher highs, while the Relative Strength Index (RSI) forms lower highs - The Moving Average Convergence Divergence (MACD) has formed a death cross, with increasing bearish histograms - We have broken down from the ascending parallel channel, and the support has now become resisance - Prices have been testing the upper resistance of the Bollinger bands, and a test of the lower support is highly likely - We have two price gaps on the 4H chart, waiting to get potentially filled - The volume is decreasing as bearish tensions increase What We Believe Although JNJ is a fundamentally sound stock, and still great for the long run, short term technicals demonstrate a potential downside. Trade Safe.
NYSE:JNJShort
by XForceGlobal